Congrats to Reshma Ramachandran MD, MPP, MHS (Yale NCSP '20–'22), winner of the 2025 Bernard Lown Award for Social Responsibility! 👏 A powerful voice for health equity. Learn More: bit.ly/reshma-lown2025 #HealthEquity #SocialResponsibility #YaleNCSP #PharmaReform #PublicHealth

Do companies continue promoting drugs granted U.S. FDA accelerated approval even after failed confirmatory trials? Yes—though less aggressively, finds Dr. Maryam Mooghali, MD, MSc’s #ASCO25 Merit Award-winning research. 🔗 meetings.asco.org/abstracts-pres…

NEW JAMA Health Forum Special Communication building on the amicus brief filed by Democracy Forward on behalf of Kushal Kadakia, Joseph Ross, & Reshma Ramachandran on the case challenging FDA's LDT Rule, which has now been vacated & not appealed by U.S. FDA. democracyforward.org/work/laborator…

The U.S. FDA says it will “radically increase efficiency” with AI and embrace “radical transparency.” But as Reshma Ramachandran told The New York Times, agency officials recently kicked off a six-city listening tour—with Pharma CEOs—behind closed doors. Here’s the scoop: nytimes.com/2025/06/10/hea…

The U.S. FDA plans to turbocharge drug reviews—down to 1-2 months from 10 months—via a new voucher program for “companies aligned with U.S. national priorities.” Can the engine handle it? Or will it blow out? @STATNews asked CRRIT’s Joseph Ross: 🔗 statnews.com/2025/06/18/fda…

These 1–2 month reviews may be dangerously fast—even with a fully staffed FDA. But as Joseph Ross told both @STATNews and Regulatory Affairs Professionals Society, mass layoffs raise real doubts about feasibility. Many key details remain TBD. More via Regulatory Affairs Professionals Society: 🔗 raps.org/news-and-artic…

More on the U.S. FDA’s new Commissioner’s National Priority Voucher (CNPV) program: As InsideHealthPolicy paraphrased CRRIT’s Reshma Ramachandran, the promised speed “raises serious concerns about the safety and efficacy of drugs rushed to market.” Full story: 🔗 insidehealthpolicy.com/inside-drug-pr…

(1/12) New in JAMA Internal Medicine: we assess the performance of U.S. FDA's Breakthrough Devices Program across its first 8 years, with a focus on: ⏲️ Review times 💡Innovation 📊 Evidence CC: Joseph Ross Reshma Ramachandran Harlan Krumholz James Johnston

Surrogate markers are increasingly being used to support U.S. FDA drug approvals instead of measuring clinical outcomes. In a new Federation of American Scientists🔬 memo, Reshma Ramachandran Joshua D. Wallach & Joseph Ross outline how FDA can make transparent & strengthen their evidence. fas.org/publication/va…

CRRIT Co-Director Reshma Ramachandran provided public comments at the Prescription Drug User Fee Act (PDUFA) VIII Kickoff Meeting U.S. FDA yesterday. Dr. Ramachandran discussed how the user fee process could be reformed to be more patient-centered & transparent.